Gold consumption upgrades of Chinese patent varieties are gradually recommended for 13 years

Business Club May 3 As a drug-using country, the total pharmaceutical market in China has increased from 157.2 billion yuan to 570.6 billion yuan in the past decade, with a compound growth rate of 15.4%.

Consumer demand for upgrading gradually emerged

In 2008, the proportion of the population over 65 years of age in China has reached 9.6%, and the proportion of the population aged 0-14 has dropped significantly. According to the international prevailing definition, China has entered an aging society. According to incomplete statistics, nearly 60% of the current 600 billion yuan in drug consumption is consumed by people aged over 60.

So far, the total number of elderly people aged over 60 in China has reached 149 million, accounting for 21.4% of the global elderly population, ranking first in the world, which is equivalent to the sum of the entire European population aged over 60, and still averaging 3.2% The speed is increasing.

From the analysis of the change in the amount of drug consumption, the per capita drug use of residents in China increased from 341 yuan in 2006 to 574 yuan in 2009, an average annual increase of 19%, but there is still a large gap between the per capita drug use amount in China and the per capita amount of US$300 per capita in developed countries. , And the difference between urban and rural areas, but also has great room for growth.

According to the survey data of the Research Group of Chinese Medicine Strategic Research Team of the China Institute of Science and Technology Information, in the early years of the Republic of China, there were 800,000 Chinese medicine practitioners in China, 500,000 in 1949, and about 270,000 people in the past three years. The initial drop was significant.

On the one hand, there is a growing demand for Chinese medicine treatment services. On the other hand, there is a delay in the development of TCM medical resources, especially TCM experts. The imbalance between supply and demand has strained TCM medical services. With the booming development of the Chinese medicine economy and the rapid increase in the demand for botanical drugs, Chinese herbal medicine resources are becoming increasingly scarce; in addition, excessive disorderly mining and deterioration of the ecological environment have also led to shortage of quality of Chinese herbal medicine resources, and wild resources have been declining year by year. Prices are rising year by year. Rare Chinese herbal medicines have entered the era of high-end consumption.

Innovation wins, variety is king

With the development of our country’s economy and the improvement of people’s living standards, people’s concept of disease prevention has shifted to prevention and health care, focusing on the timely adjustment of the state of sub-health, that is, the “prevention of illness” to “prevention of disease” in the past. Conversion. The medical model has also changed from simple disease treatment to prevention, health care, and a combination of treatment and rehabilitation. The drug consumption market has gradually expanded.

Under the background of continuous regulation and control of drug prices by national policies, extending the pharmaceutical industry chain through model innovation and product innovation to evade the risk of drug price cuts is a realistic choice for the sustainable development of pharmaceutical companies, and it is also a backdrop for the development of pharmaceutical industry enterprises in China’s special industry. A manifestation of survival adaptability. We are optimistic about the future prospects of Chinese medicine manufacturers in the field of health care products such as drug makeup and health products.

From the analysis of proprietary Chinese medicine manufacturers that have taken the lead in innovation and innovation, the old brands occupy the vast majority. We believe that this phenomenon is a reflection of the long history of traditional Chinese medicines. The forward-looking and adaptable nature of the industry's policies has also fully demonstrated the longevity of the old brand.

In 2010, about 1,169 new approvals were issued by the State Food and Drug Administration, 953 of which were approvals for newly approved products. Other new approvals were replaced with new approval numbers for old approvals of listed products. Compared with previous years, the number of new approvals has been significantly reduced. Of the 953 new approvals, 858 are chemical drugs, accounting for 90.03%; 79 are proprietary Chinese medicines, accounting for 8.29%; 16 are biological products, accounting for 1.68%. .

On October 9, 2010, the Ministry of Industry and Information Technology, the Ministry of Health, and the State Food and Drug Administration jointly issued the "Guiding Opinions on Accelerating the Structural Adjustment of the Pharmaceutical Industry." The opinion stated that for the pharmaceutical products with independent intellectual property rights, separate price-setting policies shall be given during price verification; 10, 15 and 50 autonomous knowledge shall be cultivated during the “12th Five-Year Plan” period for chemical drugs, biological drugs and traditional Chinese medicines respectively. Property rights products.

Under the guidance of emphasis on quality and encouragement of innovation, we believe that the threshold for future new drug certificates will continue to increase. Taking into account the unique R&D mechanism of proprietary Chinese medicines, the historical advantages of the old brands are obvious, and innovative Chinese pharmaceutical companies with strong R&D industrialization capabilities or external integration capabilities are also worth focusing on.

Some advantages of proprietary Chinese medicines

Compared with chemical medicines and biological products, proprietary Chinese medicines are better at treating chronic diseases, are suitable for health care and post-illness conditioning, and have certain therapeutic advantages in areas such as health care, cardiovascular and cerebrovascular diseases, and respiratory diseases that require long-term adherence to medications. . We aim to develop a variety of proprietary Chinese medicine companies that have a competitive advantage.

Trauma Surgery Series

Distal Femur Locking Plate,Tibial Platform Plates,Tibial Implant Plate,Tibia Locking Plate

Jiangsu Health Medical Technology Development Co., Ltd. , https://www.medicalhos.com